<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00667485</url>
  </required_header>
  <id_info>
    <org_study_id>15878B</org_study_id>
    <secondary_id>AVF4180s</secondary_id>
    <nct_id>NCT00667485</nct_id>
  </id_info>
  <brief_title>Rapamycin Plus Bevacizumab in Advanced Cancers</brief_title>
  <official_title>A Phase I Study of Rapamycin (Sirolimus) With Bevacizumab in Patients With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this trial is to determine the toxicity and maximum dose of rapamycin and&#xD;
      bevacizumab given together to subjects with advanced cancers. This study will also look at&#xD;
      the pharmacokinetics and antitumor activity of the combination.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Advanced Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <arm_group>
    <arm_group_label>Weekly Rapamcyin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rapamycin (liquid) taken weekly and Bevacizumab (IV infusion ) once every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daily Rapamycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily oral rapamycin (tablets) and Bevacizumab (IV infusion)once every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rapamycin (liquid)</intervention_name>
    <description>Weekly Rapamycin (liquid) 90mg (dose will be split 45mg on Day 1 and Day 2 of each week)</description>
    <arm_group_label>Weekly Rapamcyin</arm_group_label>
    <other_name>sirolimus</other_name>
    <other_name>Rapamune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Multiple doses (dose depends on time of study entry) given by IV once every 3 weeks</description>
    <arm_group_label>Daily Rapamycin</arm_group_label>
    <arm_group_label>Weekly Rapamcyin</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rapamycin (Tablets)</intervention_name>
    <description>Daily oral rapamycin (tablets) - 2 doses will be tested 4mg and 6mg</description>
    <arm_group_label>Daily Rapamycin</arm_group_label>
    <other_name>sirolimus</other_name>
    <other_name>Rapamune</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Metastatic or unresectable solid tumor for which standard treatments do not exist or&#xD;
             are no longer effective&#xD;
&#xD;
          -  Performance status of 0-1&#xD;
&#xD;
          -  Measurable or non-measurable disease&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks&#xD;
&#xD;
          -  No anticipated need of other cancer treatments within the next 4 weeks&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  Negative pregnancy test for women able to have children, agreement to use a medically&#xD;
             accepted birth control method while receiving the study drugs and for at least 2 weeks&#xD;
             after stopping, not breast feeding&#xD;
&#xD;
          -  Ability to understand and willingness to sign a written informed consent document&#xD;
&#xD;
          -  No evidence of bleeding diathesis&#xD;
&#xD;
          -  Patients without lung cancer receiving anti-coagulation treatment can participate&#xD;
&#xD;
          -  Adequate organ and marrow function:&#xD;
&#xD;
               -  ALT and AST less than or equal to 2.5 times the institutional ULN (less than 5&#xD;
                  times for patients with liver involvement)&#xD;
&#xD;
               -  hemoglobin at least 9g/dL&#xD;
&#xD;
               -  absolute neutrophil count at least 1,500/µL&#xD;
&#xD;
               -  platelets at least 100,000/µL&#xD;
&#xD;
               -  total bilirubin less than or equal to 1.5 times the institutional ULN&#xD;
&#xD;
               -  creatinine less than or equal to 1.5 times the institutional ULN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with both bevacizumab and an mTOR inhibitor is not allowed. Prior&#xD;
             treatment with both bevacizumab OR mTOR inhibitor (including rapamycin) is allowed.&#xD;
             Patients who had a grade 3 or greater side effect with either bevacizumab or an mTOR&#xD;
             inhibitor cannot take part in this study.&#xD;
&#xD;
          -  Chemotherapy or Immunotherapy within the 4 weeks of study start&#xD;
&#xD;
          -  Radiotherapy within 14 days of study start&#xD;
&#xD;
          -  Cannot be receiving any other investigational drugs or any other cancer treatments&#xD;
             while on study (with the exception of androgen ablating agents for patients with&#xD;
             prostate cancer).&#xD;
&#xD;
          -  Patients with squamous non-small cell lung cancer (NSCLC)&#xD;
&#xD;
          -  Patients with lung cancer or lung metastases:&#xD;
&#xD;
               -  on full dose anticoagulation&#xD;
&#xD;
               -  taking 325mg aspirin per day&#xD;
&#xD;
               -  on non-steroidal anti-inflammatory agents&#xD;
&#xD;
          -  HIV positive patients receiving combination anti-retroviral therapy are excluded due&#xD;
             to potential for serious infections while taking marrow suppressing agents&#xD;
&#xD;
          -  Ongoing illness or medical exclusions, including but not limited to:&#xD;
&#xD;
               -  active or ongoing infection&#xD;
&#xD;
               -  symptomatic congestive heart failure&#xD;
&#xD;
               -  uncontrolled hypertension despite optimal medical management&#xD;
&#xD;
               -  cardiac arrhythmia except paroxysmal atrial fibrillation&#xD;
&#xD;
               -  psychiatric illness/social situations that would limit compliance with study&#xD;
                  requirements&#xD;
&#xD;
               -  history of organ allograft, bone marrow or peripheral blood stem cell transplant&#xD;
&#xD;
               -  known or suspect allergy to bevacizumab or rapamycin&#xD;
&#xD;
               -  seizure disorder treated with steroid or anticonvulsant therapy&#xD;
&#xD;
               -  thrombotic or embolic events within 6 months of starting study&#xD;
&#xD;
               -  pulmonary hemorrhage/bleeding within 12 weeks of starting study (grade 3 event&#xD;
                  within 4 weeks of first dose of drug). Patients with a history of pulmonary&#xD;
                  hemorrhage/bleeding cannot be on full dose anticoagulation.&#xD;
&#xD;
               -  pulmonary fibrosis or interstitial lung disease&#xD;
&#xD;
               -  serious non-healing wound, ulcer or bone fracture&#xD;
&#xD;
               -  Major surgery, open biopsy or a traumatic injury within 4 weeks of starting study&#xD;
                  drug&#xD;
&#xD;
               -  anticipated need for major surgery while on-study&#xD;
&#xD;
               -  current use of any herbal supplements or rifampin (rifampicin)&#xD;
&#xD;
               -  prior history of hypertensive crisis or hypertensive encephalopathy&#xD;
&#xD;
               -  history of myocardial infarction or unstable angina within 6 months of starting&#xD;
                  study&#xD;
&#xD;
               -  known CNS disease&#xD;
&#xD;
               -  significant vascular disease&#xD;
&#xD;
               -  symptomatic peripheral vascular disease&#xD;
&#xD;
               -  evidence of bleeding diathesis or coagulopathy&#xD;
&#xD;
               -  core biopsy or other minor surgical procedure (except placement of vascular&#xD;
                  access device) within 7 days of starting study&#xD;
&#xD;
               -  history of abdominal fistula, gastrointestinal perforation, or intra-abdominal&#xD;
                  abscess within 6 months of study start&#xD;
&#xD;
               -  proteinuria at screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ezra Cohen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>April 24, 2008</study_first_submitted>
  <study_first_submitted_qc>April 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2008</study_first_posted>
  <last_update_submitted>January 16, 2014</last_update_submitted>
  <last_update_submitted_qc>January 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

